JP2023535074A5 - - Google Patents

Info

Publication number
JP2023535074A5
JP2023535074A5 JP2023504636A JP2023504636A JP2023535074A5 JP 2023535074 A5 JP2023535074 A5 JP 2023535074A5 JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023535074 A5 JP2023535074 A5 JP 2023535074A5
Authority
JP
Japan
Application number
JP2023504636A
Other languages
Japanese (ja)
Other versions
JP2023535074A (ja
JPWO2022020108A5 (https=
JP7828947B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/041003 external-priority patent/WO2022020108A1/en
Publication of JP2023535074A publication Critical patent/JP2023535074A/ja
Publication of JPWO2022020108A5 publication Critical patent/JPWO2022020108A5/ja
Publication of JP2023535074A5 publication Critical patent/JP2023535074A5/ja
Application granted granted Critical
Publication of JP7828947B2 publication Critical patent/JP7828947B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023504636A 2020-07-23 2021-07-09 筋標的化複合体およびそれらの使用 Active JP7828947B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063055785P 2020-07-23 2020-07-23
US63/055,785 2020-07-23
US202063061842P 2020-08-06 2020-08-06
US63/061,842 2020-08-06
US202063069078P 2020-08-23 2020-08-23
US63/069,078 2020-08-23
US202163143831P 2021-01-30 2021-01-30
US63/143,831 2021-01-30
US202163181450P 2021-04-29 2021-04-29
US63/181,450 2021-04-29
PCT/US2021/041003 WO2022020108A1 (en) 2020-07-23 2021-07-09 Muscle-targeting complexes and uses thereof

Publications (4)

Publication Number Publication Date
JP2023535074A JP2023535074A (ja) 2023-08-15
JPWO2022020108A5 JPWO2022020108A5 (https=) 2024-07-18
JP2023535074A5 true JP2023535074A5 (https=) 2024-07-18
JP7828947B2 JP7828947B2 (ja) 2026-03-12

Family

ID=79728348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504636A Active JP7828947B2 (ja) 2020-07-23 2021-07-09 筋標的化複合体およびそれらの使用

Country Status (7)

Country Link
US (1) US20230287108A1 (https=)
EP (1) EP4185329A4 (https=)
JP (1) JP7828947B2 (https=)
CN (2) CN116194470B (https=)
AU (1) AU2021313058A1 (https=)
CA (1) CA3186755A1 (https=)
WO (1) WO2022020108A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283531A2 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
CA3174286A1 (en) 2020-04-02 2021-10-07 Robert PLACE Targeted inhibition using engineered oligonucleotides
KR20230044242A (ko) * 2020-07-23 2023-04-03 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
WO2022270585A1 (ja) 2021-06-23 2022-12-29 日本新薬株式会社 アンチセンスオリゴマーの組み合わせ
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2023168427A1 (en) * 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025160275A1 (en) 2024-01-24 2025-07-31 Arrowhead Pharmaceuticals, Inc. Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof
WO2025215092A1 (en) * 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130164A2 (en) * 2010-04-13 2011-10-20 The Regents Of The University Of California Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
PE20141114A1 (es) * 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
TWI769982B (zh) * 2015-06-24 2022-07-11 日商Jcr製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
FR3049951A1 (fr) * 2016-04-12 2017-10-13 Univ Rabelais Francois Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
RU2753493C2 (ru) 2016-12-15 2021-08-17 Эббви Байотерапьютикс Инк. Анти-ох40 антитела и их применение
RU2771292C2 (ru) 2017-10-14 2022-04-29 Эббви Инк. Конъюгаты анти-cd71 активируемое антитело-лекарственное средство и способы их применения
AR126019A1 (es) * 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP7576542B2 (ja) * 2018-08-02 2024-10-31 ダイン セラピューティクス,インコーポレーテッド 筋標的化複合体およびそれらの使用
WO2020028842A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
GB2595980B (en) * 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN116348138A (zh) * 2020-07-23 2023-06-27 达因疗法公司 抗转铁蛋白受体(tfr)抗体及其用途
AU2021318851A1 (en) * 2020-07-23 2023-03-16 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
KR20230046297A (ko) * 2020-07-23 2023-04-05 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
US20230346966A1 (en) * 2020-07-23 2023-11-02 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
KR20230044242A (ko) * 2020-07-23 2023-04-03 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도

Similar Documents

Publication Publication Date Title
JP2023535074A5 (https=)
BR102021010467A2 (https=)
CN305907642S (https=)
CN305906510S (https=)
CN305536462S (https=)
CN305536179S (https=)
CN305536127S (https=)
CN305534880S (https=)
CN305533044S (https=)
CN305532097S (https=)
CN305530115S (https=)
CN305529556S (https=)
CN305529050S (https=)
CN305528852S (https=)
CN305528420S (https=)
CN305906862S (https=)
CN305904583S (https=)
CN305903951S (https=)
CN305895826S (https=)
CN305884863S (https=)
CN305776263S (https=)
CN305773909S (https=)
CN305770607S (https=)
CN305769368S (https=)
CN305769037S (https=)